The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.


Journal

The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123

Informations de publication

Date de publication:
May 2019
Historique:
received: 22 05 2018
revised: 20 01 2019
accepted: 21 01 2019
pubmed: 25 3 2019
medline: 7 11 2019
entrez: 24 3 2019
Statut: ppublish

Résumé

Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. We included patients aged 18-64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109). Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health. Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.

Sections du résumé

BACKGROUND BACKGROUND
Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder.
METHODS METHODS
We included patients aged 18-64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ
FINDINGS RESULTS
Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109).
INTERPRETATION CONCLUSIONS
Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health.
FUNDING SOURCE BACKGROUND
Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.

Identifiants

pubmed: 30902669
pii: S2215-0366(19)30048-3
doi: 10.1016/S2215-0366(19)30048-3
pmc: PMC7646282
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-436

Subventions

Organisme : Medical Research Council
ID : MR/M008436/1
Pays : United Kingdom

Investigateurs

Silvia Amoretti (S)
Manuel Arrojo (M)
Grégoire Baudin (G)
Stephanie Beards (S)
Miquel Bernardo (M)
Julio Bobes (J)
Chiara Bonetto (C)
Bibiana Cabrera (B)
Angel Carracedo (A)
Thomas Charpeaud (T)
Javier Costas (J)
Doriana Cristofalo (D)
Pedro Cuadrado (P)
Covadonga M Díaz-Caneja (CM)
Aziz Ferchiou (A)
Nathalie Franke (N)
Flora Frijda (F)
Enrique García Bernardo (E)
Paz Garcia-Portilla (P)
Emiliano González (E)
Kathryn Hubbard (K)
Stéphane Jamain (S)
Estela Jiménez-López (E)
Marion Leboyer (M)
Gonzalo López Montoya (G)
Esther Lorente-Rovira (E)
Camila Marcelino Loureiro (C)
Giovanna Marrazzo (G)
Covadonga Martínez (C)
Mario Matteis (M)
Elles Messchaart (E)
Ma Dolores Moltó (MD)
Juan Nacher (J)
Ma Soledad Olmeda (MS)
Mara Parellada (M)
Javier González Peñas (J)
Baptiste Pignon (B)
Marta Rapado (M)
Jean-Romain Richard (JR)
José Juan Rodríguez Solano (JJ)
Laura Roldán Díaz (L)
Mirella Ruggeri (M)
Pilar A Sáiz (PA)
Emilio Sánchez (E)
Julio Sanjuán (J)
Crocettarachele Sartorio (C)
Franck Schürhoff (F)
Fabio Seminerio (F)
Rosana Shuhama (R)
Lucia Sideli (L)
Simona A Stilo (SA)
Fabian Termorshuizen (F)
Sarah Tosato (S)
Anne-Marie Tronche (AM)
Daniella van Dam (D)
Elsje van der Ven (E)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Br J Psychiatry. 2018 Apr;212(4):227-233
pubmed: 29557758
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Lancet Psychiatry. 2017 Aug;4(8):643-648
pubmed: 28259650
Neuropharmacology. 2017 Sep 15;124:89-104
pubmed: 28634109
Psychol Med. 2019 Jul;49(9):1574-1580
pubmed: 30176957
Addiction. 2015 Dec;110(12):1941-50
pubmed: 26234170
BMC Med. 2004 Apr 28;2:13
pubmed: 15115547
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):329-35
pubmed: 12111025
JAMA Psychiatry. 2016 Mar;73(3):300-1
pubmed: 26864618
Transl Psychiatry. 2016 Nov 29;6(11):e961
pubmed: 27898071
Psychol Med. 2018 Oct;48(14):2346-2352
pubmed: 29382407
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Addiction. 2014 Oct;109(10):1686-94
pubmed: 24894801
Nature. 2015 Sep 24;525(7570):S14
pubmed: 26398733
Addiction. 2017 Mar;112(3):477-485
pubmed: 27743424
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
Psychol Med. 2006 Oct;36(10):1441-6
pubmed: 16854250
Annu Rev Med. 2016;67:453-66
pubmed: 26515984
Neurosci Biobehav Rev. 2011 Aug;35(8):1779-87
pubmed: 21530584
J Forensic Sci. 2008 Jan;53(1):90-4
pubmed: 18279244
World Psychiatry. 2016 Oct;15(3):195-204
pubmed: 27717258
Drug Test Anal. 2015 Mar;7(3):255-8
pubmed: 25069834
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
Curr Psychiatry Rep. 2016 Feb;18(2):12
pubmed: 26781550
Biol Psychiatry. 2016 Apr 1;79(7):549-56
pubmed: 26386480
Arch Gen Psychiatry. 2005 Sep;62(9):975-83
pubmed: 16143729
Drug Test Anal. 2018 Apr;10(4):628-635
pubmed: 29441730

Auteurs

Marta Di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK; South London and Maudsley NHS Mental Health Foundation Trust, London, UK. Electronic address: marta.diforti@kcl.ac.uk.

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.

Tom P Freeman (TP)

Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.

Giada Tripoli (G)

Institute of Psychiatry, Psychology and Neuroscience and Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Harriet Quigley (H)

Institute of Psychiatry, Psychology and Neuroscience and Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.

Victoria Rodriguez (V)

Institute of Psychiatry, Psychology and Neuroscience and Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.

Hannah E Jongsma (HE)

Department of Psychiatry, University of Cambridge, Cambridge, UK; Psylife Group, Division of Psychiatry, University College London, London, UK.

Laura Ferraro (L)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.

Caterina La Cascia (C)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.

Daniele La Barbera (D)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Domenico Berardi (D)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Andrei Szöke (A)

INSERM U955, Equipe 15, Institut National de la Santé et de la Recherche Médicale, Créteil, Paris, France.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), Madrid, Spain.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, Paris, France.

Eva Velthorst (E)

Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital clinic, Department of Medicine, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Cristina Marta Del-Ben (CM)

Division of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Paulo Rossi Menezes (PR)

Department of Preventative Medicine, Faculdade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil.

Jean-Paul Selten (JP)

Rivierduinen Institute for Mental Health Care, Leiden, Netherlands.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK; CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, London, UK.

Bart Pf Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, Netherlands.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.

Pak C Sham (PC)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK; Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Jim van Os (J)

Institute of Psychiatry, Psychology and Neuroscience and Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK; Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

Cathryn M Lewis (CM)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK.

Michael Lynskey (M)

Department of Addiction, Institute of Psychiatry, King's College London, London, UK.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Robin M Murray (RM)

Institute of Psychiatry, Psychology and Neuroscience and Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH